Edward Kormylo, DPM
Foot & Ankle Surgery · East Patchogue, NYNPI 1134373467
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $35,613 of the $45,261 with a category attached, or 78.7%. Stryker accounts for 96.8% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2022 at $17,325 and has fallen 73.2% since, to $4,647 in 2025. Among foot & ankle surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 120 payments — averaging $377.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$44K
- Organogenesis Inc.$258
- Treace Medical Concepts, Inc.$230
- Melinta Therapeutics, LLC$150
- AbbVie$138
- Integra Lifesciences Corporation$100
- plus $592 from 19 others
Across 4 payments — averaging $30,625 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Royal Biologics, Inc.$123K
What the payments were for
- Consulting fees$35,61379%
- Travel & lodging$6,31814%
- Food & beverage$3,3307%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker(2 entities) | 65 | $43,793 |
| Organogenesis Inc. | 5 | $258 |
| Treace Medical Concepts, Inc. | 1 | $230 |
| Melinta Therapeutics, LLC | 8 | $150 |
| AbbVie | 5 | $138 |
| Integra Lifesciences Corporation | 4 | $100 |
| Sandoz | 4 | $82 |
| Tactile Systems Technology Inc | 4 | $61 |
| Merck | 4 | $57 |
| Linvatec Corporation | 1 | $50 |
| Gotham Surgical Solutions & Devices, Inc. | 1 | $50 |
| Amgen | 3 | $42 |
| Smith+Nephew | 2 | $33 |
| Bioventus LLC | 2 | $33 |
| Kerecis Limited | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $19 |
| Solventum Corporation | 1 | $19 |
| Henry Schein Medical Systems, Inc. | 1 | $17 |
| KCI USA, Inc. | 1 | $17 |
| Misonix Inc | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $15 |
| Glenmark Therapeutics Inc. | 1 | $14 |
| Zyla Life Sciences, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORTHOLOC 3DI$9,837
- EASYFUSE$7,885
- ORTHOLOC 2 LAPIFUSE$6,637
- VARIAX$5,950
- 7 X 23MM CITRELOCK IMPLANT$5,363
- T2$5,163
- CLARIFIX CRYOTHERAPY DEVICE$3,500
- VALOR$3,325
- SALVATION$3,325
- CITREFIX$3,150
- PRIME SERIES$2,996
- SONICANCHOR$2,975
- PROstep$2,975
- N/A$2,100
- HOFFMANN$2,100
- ALLOWRAP$1,400
- FUSEFORCE$1,050
- INFINITY$604
- INBONE$595
- ASNIS$279
How this compares
$45,261 in reported general payments places this provider in the 95th percentile of 652 foot & ankle surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JubliaEfinaconazole | 22 | $29,343 |
| ErtapenemErtapenem Sodium | 19 | $14,888 |
| SantylCollagenase Clostridium Hist. | 14 | $5,351 |
| Pregabalin | 143 | $2,918 |
| Ketoconazole | 122 | $2,416 |
| Linezolid | 17 | $1,624 |
| Fluorouracil | 17 | $1,434 |
| Fluconazole | 26 | $961 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 154 | $658 |
| Diclofenac Sodium | 27 | $575 |
| Terbinafine Hcl | 74 | $529 |
| Allopurinol | 59 | $416 |
| Meloxicam | 100 | $340 |
| Levofloxacin | 48 | $295 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 42 | $270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia | $19 | $29,34322 claims |
| Smith+NephewSantyl | $33 | $5,35114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 652 foot & ankle surgery providers in New York.
Other foot & ankle surgery in East Patchogue
- Brittany HerveyEast Patchogue$22K
- James McWilliamHarrison$4.7M
- Jonathan DelandNew York$4M
- George Vitole Roy$2.5M
- Constantine DemetracopoulosNew York$888K
- Anne JohnsonNew York$815K
- Scott EllisNew York$597K
- John KennedyNew York$534K
- Michael KellerKingston$532K
- Judith BaumhauerRochester$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.